Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of pivekimab sunirine with venetoclax and azacitidine in newly diagnosed AML unfit for intensive chemotherapy
MOH_2026-04-16_015771Phase 3Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pivekimab sunirine, venetoclax and azacitidine in acute myeloid leukemia (AML) (4 arms), sponsored by AbbVie Inc. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
pivekimab sunirinevenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2026-04-16_015771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-04-16_015771.